Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN.

Eur Urol. 2020 Feb 6. pii: S0302-2838(19)30958-3. doi: 10.1016/j.eururo.2019.12.014. [Epub ahead of print] No abstract available.


Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.


High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.


Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.

Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P, Bergman CC, Auriault ML, Vordos D, Taille A, Culine S, Allory Y.

Mod Pathol. 2018 Aug;31(8):1270-1281. doi: 10.1038/s41379-018-0023-9. Epub 2018 Feb 21.


Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate.

Giton F, Sirab N, Franck G, Gervais M, Schmidlin F, Ali T, Allory Y, de la Taille A, Vacherot F, Loric S, Fiet J.

J Steroid Biochem Mol Biol. 2015 Aug;152:89-100. doi: 10.1016/j.jsbmb.2015.05.002. Epub 2015 May 6.


Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.

Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A, Terry S.

Int J Mol Sci. 2013 Jul 10;14(7):14301-20. doi: 10.3390/ijms140714301.


Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells.

Sirab N, Terry S, Giton F, Caradec J, Chimingqi M, Moutereau S, Vacherot F, de la Taille A, Kouyoumdjian JC, Loric S.

Int J Cancer. 2012 Sep 15;131(6):1297-306. doi: 10.1002/ijc.27384. Epub 2012 Jan 27.


Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A.

Cancer Res. 2010 Nov 15;70(22):9253-64. doi: 10.1158/0008-5472.CAN-10-1447. Epub 2010 Nov 2.


Is GAPDH a relevant housekeeping gene for normalisation in colorectal cancer experiments?

Caradec J, Sirab N, Revaud D, Keumeugni C, Loric S.

Br J Cancer. 2010 Oct 26;103(9):1475-6. doi: 10.1038/sj.bjc.6605851. Epub 2010 Sep 21. No abstract available.


'Desperate house genes': the dramatic example of hypoxia.

Caradec J, Sirab N, Keumeugni C, Moutereau S, Chimingqi M, Matar C, Revaud D, Bah M, Manivet P, Conti M, Loric S.

Br J Cancer. 2010 Mar 16;102(6):1037-43. doi: 10.1038/sj.bjc.6605573. Epub 2010 Feb 23.


Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A.

Prostate. 2009 Dec 1;69(16):1774-80. doi: 10.1002/pros.21027.


Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.

Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Gil Diez de Medina S, Moutereau S, Maillé P, Soyeux P, Abbou C, Salomon L, Vacherot F, de La Taille A, Loric S, Allory Y.

J Pathol. 2008 Dec;216(4):460-70. doi: 10.1002/path.2427.


Supplemental Content

Support Center